These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 9587683

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Innovations in the systemic therapy of prostate cancer.
    Shepard DR, Raghavan D.
    Nat Rev Clin Oncol; 2010 Jan; 7(1):13-21. PubMed ID: 19997075
    [Abstract] [Full Text] [Related]

  • 28. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
    Gomella LG, Zeltser I, Valicenti RK.
    Urology; 2003 Dec 29; 62 Suppl 1():46-54. PubMed ID: 14747041
    [Abstract] [Full Text] [Related]

  • 29. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
    Labrie F, Dupont A, Bélanger A, Lacourcière Y, Monfette JE, Monfette G.
    Ann Urol (Paris); 1986 Dec 29; 20(2):98-106. PubMed ID: 2940959
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Treatment options in androgen-independent prostate cancer.
    Lara PN, Meyers FJ.
    Cancer Invest; 1999 Dec 29; 17(2):137-44. PubMed ID: 10071598
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Current treatment of advanced prostate cancer.
    Ismail M, Gomella LG.
    Tech Urol; 1997 Dec 29; 3(1):16-24. PubMed ID: 9170220
    [Abstract] [Full Text] [Related]

  • 36. Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.
    Payne H, Mason M.
    Br J Cancer; 2011 Nov 22; 105(11):1628-34. PubMed ID: 22009028
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO, Crawford ED.
    Curr Opin Urol; 2013 May 22; 23(3):208-13. PubMed ID: 23492838
    [Abstract] [Full Text] [Related]

  • 39. The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy.
    Soloway MS.
    Prog Clin Biol Res; 1990 May 22; 350():141-8. PubMed ID: 2201040
    [No Abstract] [Full Text] [Related]

  • 40. Hormonal therapy: historical perspective to future directions.
    Mcleod DG.
    Urology; 2003 Feb 22; 61(2 Suppl 1):3-7. PubMed ID: 12667881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.